The FDA has granted Enzo Biochem an expanded Emergency Use Authorization (EUA) for the rapid extraction method included in its GENFLEX Molecular System for COVID-19.

The New York-based company says its test system can detect the genetic variants of the coronavirus that causes COVID-19, including the Delta variant first identified in India and the Lambda variant first detected in Peru.

Enzo says the faster extraction process can reduce the time laboratories take to complete a COVID-19 test by more than an hour, enabling more test runs on a single instrument.